ClinicalTrials.gg
Status unknownNCT04044222Updated Sep 14, 2022

A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard Chemotherapy

A Phase 3 interventional study of Sintilimab and Carboplatin in Classic Hodgkin's Lymphoma, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-14.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 56 studies in Hodgkin Disease with a site in China — 27 open to participants now, 30 under way, 3 of them phase 3. Hodgkin Disease · China.

Planned enrollment
4th of 53
240 · median 75
Started
2019
with 6 others
Phase 3
5 of 56
2 open now
Registered
20th of 56
by date
Lead sponsor
2 of 56
Innovent Biologics (Suzhou) Co. Ltd.

Among the 56 studies in Hodgkin Disease with a site in China, this one is the 4th largest by planned enrollment of the 53 interventional ones that give a count, is one of 7 that started in 2019, is one of 5 in phase 3, and was the 20th registered.

Hodgkin Disease

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

27 of the 56 studies in Hodgkin Disease with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Hodgkin Disease with a site in China, or all of them as a file.
02

Study summary

This phase III trial studies the side effects of sintilimab to see how well it works when given together with ifosfamide, carboplatin, and etoposide in treating patients with classic Hodgkin lymphoma that does not respond to first-line standard chemotherapy.

Read the detailed description

randomized, double-blind, two arms , multicenter

03

Conditions studied

  • Classic Hodgkin's Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed
  2. Histopathologically confirmed cHL
  3. Failed standard combination chemotherapy
  4. One (Lugano 2014)
  5. (ECOG) of 0-1
  6. Male or female aged ≥18 years
  7. Patients must have adequate organ and bone marrow function

Exclusion criteria

Exclusion Criteria:

  1. Patients must not have known central nervous system (CNS) involvement
  2. Patients must not have had prior exposure to any including anti-PD-L1 agents, anti-PD-L2 agents, or anti-CTLA-4 monoclonal antibodies
  3. Patients may not simultaneously participate in another interventional clinical study
  4. Patients may not receive any other agents within 4 weeks of study registration
  5. Patients may not receive any other form of therapy within 4 weeks prior to the first dose of study drug
  6. Patients may not receive within 4 weeks prior to the first dose of study drug (or plan to receive live attenuated vaccines during the study period)
  7. Patients with known immunodeficiency are ineligible
  8. Patients with known active TB (Bacillus tuberculosis) are ineligible
  9. Patients must not have had prior stem cell transplantation or allogeneic organ transplantation
  10. Patients must not be pregnant or breastfeeding
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Treatment (Sintilimab, etoposide, ifosfamide, carboplatin)

    Patients receive sintilimab IV on day 1, etoposide IV on days 1-3 of courses 1-6, carboplatin IV on day 2 of courses 1-6, and ifosfamide IV on day 1-3 of courses 1-6. Sintilimab in combination with ICE chemotherapy repeats every 21 days for 6 courses.

    Biological: Sintilimab · Drug: Carboplatin · Drug: Etoposide · Drug: Ifosfamide

  • Experimental
    Treatment (placebo, etoposide, ifosfamide, carboplatin)

    Patients receive placebo IV on day 1, etoposide IV on days 1-3 of courses 1-6, carboplatin IV on day 2 of courses 1-6, and ifosfamide IV on day 1-3 of courses 1-6. Placebo in combination with ICE chemotherapy repeats every 21 days for 6 courses.

    Drug: Placebo · Drug: Carboplatin · Drug: Etoposide · Drug: Ifosfamide

Interventions

06

What researchers measure

Primary outcomes

  1. PFS

    Time frame: 44months

07

Study locations

1 of 1 sites recruiting
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2019 (actual). Primary completion is estimated for Jul 2023, 45 months after the start.

Of 33 phase 3 interventional studies under Hodgkin Disease, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 108. This study's planned 45 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2019
First posted
Aug 5, 2019
StartActual
Oct 21, 2019
Primary completionEst.
Jul 30, 2023
CompletionEst.
Dec 31, 2024
Last update
Sep 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04044222
Responsible party
Sponsor
First posted
Aug 5, 2019
Start date
Oct 21, 2019
Primary completion
Jul 30, 2023 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Sep 14, 2022

Study contacts

Ronghua Zhang
Contact
ronghua.zhang@innoventbio.com
15267110561
Hui Zhou
Contact
hui.zhou@innoventbio.com
86-021-31837200

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sintilimab

Start the discussion